BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

EvoGenix Limited 

343 Royal Parade

Melbourne  Victoria  3052  Australia
Phone: 61-0-3-9662-7322 Fax: 61-0-3-9662-7166


SEARCH JOBS


EvoGenix has rapidly established itself as a global player in the antibody sector creating a powerful proprietary technology platform and industry expertise in the identification and development of antibody-based drugs.

Following its acquisition of California-based biotechnology company Absalus Incorporated in 2005 EvoGenix now offers a fully integrated approach to creating novel antibody products, rapidly converting a non-human antibody to a potent fully humanized product suitable for administration to patients.

In August 2005 EvoGenix completed a capital raising and listing of its shares on the Australian Stock Exchange (ASX:EGX) with a current market cap in excess of AU$100M.

The EvoGenix business strategy works by applying its technology platform in both:

  • R&D collaborations with other companies to assist them in the development of improved protein and antibody therapeutics, and

  • Developing an internal pipeline of antibody products.

    EvoGenix continues to focus technology and business development capabilities at its Melbourne site with US-based EvoGenix Incorporated responsible for the identification and assessment of novel product opportunities.

    EvoGenix current pipeline of therapeutic products include those for the treatment of bone disease (EGX-010), melanoma/lung cancer (EGX-150), infectious disease (EGX-220), solid cancers (EGX-160) and acute leukemia (EGX-140).

    The EvoGenix technology platform consists of the following components:

    Superhumanization™ represents an entirely novel method for converting a non-human antibody, which would elicit an immune reaction if administered to humans, into a "humanized" form, which can be administered safely to patients over an extended time frame. In conventional humanization the starting antibody is matched on the basis of sequence homology to a human framework. In Superhumanization™ the frameworks are chosen on the basis of matched canonical structure, resulting in products that are less immunogenic, yet retain most properties of the starting antibody.

    EvoGene™ offers a truly unique approach to the fine tuning and optimization of protein products. By seamlessly linking a highly effective RNA-based mutagenesis approach to an efficient ribosome display procedure EvoGene™ enables the selection of highly optimized variants from very high diversity libraries of mutants whilst requiring a fraction of the resources of competitive approaches such as saturation mutagenesis. It is not only more efficient, but also more effective for protein fine-tuning when compared with technologies such as gene shuffling, since changes to the targeted protein are minimized and can readily be restricted to those contributing directly to the improvement in properties. EvoGeneTM can be applied to the test tube evolution of any protein product - providing novel products with greater activity, potency, specificity, stability or expression.

    Partners

    EvoGenix currently has collaborative research and commercialization agreements with GlaxoSmithKline (GSK), CSL Limited and Vegenics Limited.
    Under the multi-project GSK agreement EvoGenix undertook to improve the GSK protein-based products using the EvoGeneTM technology. EvoGenix reported March 2007 the success of the initial project, exceeding the success-based milestone of 20-fold improvement.

    Last Updated: 04-10-07

     Key Statistics


    Email: r.crombie@evogenix.com.au
    Ownership: Public

    Web Site: EvoGenix Limited
    Employees:
    Symbol: EGX.AX
     



  • Industry
    Biotechnology






     Company News
    EvoGenix Limited (EGX.AX) Announces Results of Exercise of the Company's Series 1 Options 6/2/2009 11:32:28 AM    More...
    EvoGenix Limited (EGX.AX) to Commence Second Project with GlaxoSmithKline (GSK) 8/16/2007 9:31:54 AM    More...
    Shareholders Approve Peptech Limited and EvoGenix Limited (EGX.AX) Merger 8/9/2007 8:21:02 AM    More...
    EvoGenix Limited (EGX.AX) Achieves Milestone in Collaboration with GlaxoSmithKline (GSK) 3/26/2007 12:09:04 PM    More...
    EvoGenix Limited (EGX.AX) and Vegenics Limited Announce Collaboration 2/27/2007 3:08:35 PM    More...
    EvoGenix Limited (EGX.AX) Granted US Patent 1/24/2007 1:05:40 PM    More...
    EvoGenix Limited (EGX.AX) To Collaborate With US National Institutes of Health (NIH) 11/2/2006 4:31:05 PM    More...
    EvoGenix Limited (EGX.AX) Completes Project With GlaxoSmithKline (GSK) 10/24/2006 1:51:52 PM    More...
    Innexus Biotechnology Inc. (IXS) Announces Collaboration Focused On Developing Novel Antiviral Antibodies 10/3/2006 11:44:29 AM    More...
    EvoGenix Limited (EGX.AX) Announces Antibody Collaboration With CSL Limited (CMXHF.PK) 6/1/2006 10:27:16 AM    More...
    12